OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0000793171

Vitro Biopharma, Inc.

Vitro Biopharma, Inc. (CIK 0000793171, EIN 84-1012042) reported revenue of $2.06 million ($2,056,818) for FY2025 (2024-11-01 to 2025-10-31) and net income of -$10.85 million (-$10,851,802) for FY2025 (2024-11-01 to 2025-10-31), as filed in its 10-K filed 2026-02-13 (accession 0001493152-26-006592).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends October 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0000793171
EIN84-1012042
SIC industry code2836 Biological Products, (No Diagnostic Substances)
State or country of incorporationNV
Fiscal year endOctober 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_4zkcczqcga7bte49dtmgg95rbr
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$2,056,818FY20252024-11-01 to 2025-10-3110-K2026-02-130001493152-26-006592Revenues
Net income-$10,851,802FY20252024-11-01 to 2025-10-3110-K2026-02-130001493152-26-006592NetIncomeLoss
Total assets$4,929,210FY2025as of 2025-10-3110-K2026-02-130001493152-26-006592Assets
Total liabilities$21,262,877FY2025as of 2025-10-3110-K2026-02-130001493152-26-006592Liabilities
Stockholders' equity-$16,333,667FY2025as of 2025-10-3110-K2026-02-130001493152-26-006592StockholdersEquity
Operating cash flow-$2,537,843FY20252024-11-01 to 2025-10-3110-K2026-02-130001493152-26-006592NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$2.44 per shareFY20252024-11-01 to 2025-10-3110-K2026-02-130001493152-26-006592EarningsPerShareDiluted
Shares outstanding4,517,651 sharesFY2025as of 2026-02-1310-K2026-02-130001493152-26-006592EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2016-2025, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20252024-11-01 to 2025-10-31$2,056,81810-K2026-02-130001493152-26-006592
RevenueFY20242023-11-01 to 2024-10-31$1,855,64410-K2026-02-130001493152-26-006592
RevenueFY20232022-11-01 to 2023-10-31$1,763,45110-K2025-01-280001493152-25-003942
Net incomeFY20252024-11-01 to 2025-10-31-$10,851,80210-K2026-02-130001493152-26-006592
Net incomeFY20242023-11-01 to 2024-10-31-$9,873,56010-K2026-02-130001493152-26-006592
Net incomeFY20232022-11-01 to 2023-10-31-$5,356,71710-K2025-01-280001493152-25-003942

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2026-09-182026-07-310001493152-26-043284form10-q.htm
10-Q2026-06-152026-04-300001493152-26-028655form10-q.htm
10-Q2026-03-162026-01-310001493152-26-010236form10-q.htm
10-K2026-02-132025-10-310001493152-26-006592form10-k.htm
10-Q2025-09-122025-07-310001641172-25-027168form10-q.htm
10-Q2025-06-202025-04-300001641172-25-015758form10-q.htm
10-Q2025-03-202025-01-310001493152-25-011003form10-q.htm
10-K2025-01-282024-10-310001493152-25-003942form10-k.htm
10-Q2024-09-162024-07-310001493152-24-036326form10-q.htm
10-Q2024-05-312024-04-300001493152-24-022030form10-q.htm
10-Q2024-03-142024-01-310001493152-24-009929form10-q.htm
10-K2024-01-292023-10-310001493152-24-004126form10-k.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0000793171published by the sourcedata.sec.gov/submissions/CIK0000793171.json2026-10-21
Employer Identification Number (EIN) · US-EIN84-1012042published by the sourcedata.sec.gov/submissions/CIK0000793171.json2026-10-21

Former names

NameFromTo
VITRO DIAGNOSTICS INC1996-12-132021-10-20

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0000793171.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0000793171.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000793171" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000793171/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000793171/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"793171"}

On SEC EDGAR

About this data